



CONTACT:
Investor Relations
David Isserman
877-895-5647
IR@nutrapharma.com

NUTRA PHARMA CEO OUTLINES CORPORATE STRATEGY ON MACREPORT.NET

Boynton Beach, FL. – April 11, 2006 - Nutra Pharma Corp., (OTCBB: NPHC) a biotechnology company that is developing drugs for HIV and Multiple Sclerosis (MS), has today announced that its Chairman and Chief Executive Officer, Rik J. Deitsch, has recorded an online interview with The MacReport.Net.

In the interview, Mr. Deitsch discusses Nutra Pharma's current activities as well as their focus and strategy.

You can access the interview by going to:
<http://www.macreport.net/featured/NPHC/company.asp>

"We are excited about the opportunity to explain the Company's business and strategy on The MacReport.Net," stated Rik J Deitsch, Nutra Pharma's Chairman and Chief Executive Officer. "The Company is growing rapidly and this interview will help educate our current and potential shareholders about our current business strategy," he concluded.

About MacReport.Net

MacReport.Net is a financial services network that takes a 3 dimensional approach to disseminate information and increase exposure to the Wall Street community as well as potential investors.

<http://www.MacReport.net>

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

<http://www.NutraPharma.com>

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking

statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The interview on MacReport.net should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

###